Laden.... Wacht alsjeblieft even.
Bedrijfsprofiel
Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas:
- manufacturing of diagnosis tests for own account;
- sale of diagnosis tests supplied by other manufacturers of semi-finished products;
- research and development services for third party;
- sale of licenses;
- sale of biological reagents.
Bron:
Cofisem
-
laatste update:
06 Dec 2024
Bestuurders
| Chairman and Chief Executive Officer | Larry Abensur | ||||
| Deputy CEO | Oren Bitton | ||||
| Deputy CEO | Thomas Lamy | ||||
| Deputy CEO | Thierry Paper | ||||
| Bron: Cofisem - laatste update: 06 Dec 2024 | |||||
Kerncijfers
| Millenium | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Net sales | 92.978 | 196.587 | 382.533 | 153.895 | 34.230 |
| Consumed purchases | 15.132 | ||||
| Labour costs | 36.061 | 21.437 | 17.248 | 14.579 | 8.131 |
| Operating profit | -36.146 | 44.604 | 140.655 | 45.734 | 1.297 |
| Income tax | -2.555 | 8.571 | 32.937 | 12.149 | -216 |
| Net income | -37.122 | 15.658 | 104.004 | 31.369 | 1.116 |
| Net consolidated income (Group share) | -36.946 | 15.614 | 104.004 | 31.369 | 1.116 |
| Fiscal year end | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | French_GAAP | French_GAAP | French_GAAP | French_GAAP | French_GAAP |
| Bron: Cofisem - laatste update: 06 Dec 2024 | |||||
Aandeelhoudersinformatie
Adres
Biosynex
22 Boulevard Sébastien Brant
FR-67400
Illkirch-Graffenstaden
France
Telefoonnummer:
+33 (0)3 88 78 78 87
Fax:
+33 (0)3 88 78 76 78
Bron:
Cofisem
-
laatste update:
06 Dec 2024